Use of selexipag in a teenage patient with pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a chronic, progressive, multifactorial disease. Currently, combination therapy is an attractive option for PAH management because three pathways (endothelin, nitric oxide, and prostacyclin) are involved in this disease. Selexipag is a novel oral prostacyclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bravo-Valenzuela, Nathalie Jeanne Magioli, Navarro, Flavia, Silva, Socrates Pereira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918021/
https://www.ncbi.nlm.nih.gov/pubmed/33679065
http://dx.doi.org/10.4103/apc.APC_63_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918021/
https://www.ncbi.nlm.nih.gov/pubmed/33679065
http://dx.doi.org/10.4103/apc.APC_63_19

Ejemplares similares